Peptides for Sexual Health & Hormonal

Peptide compounds in sexual health and hormonal regulation divide into two distinct groups: GnRH analogues that control the hormonal axis, and melanocortin-pathway compounds that target sexual function directly.

The 12 approved compounds are dominated by GnRH agonists and antagonists — goserelin, leuprolide, triptorelin, degarelix, relugolix, elagolix — used across prostate cancer, endometriosis, precocious puberty, and fertility medicine. Bremelanotide (Vyleesi) is the notable outlier: the only approved melanocortin-based treatment for hypoactive sexual desire disorder, and a compound with an unusual development history that began in sunless tanning research.

The research tier includes PT-141 (bremelanotide’s earlier research-grade formulation), melanotan II, and kisspeptin-10 — compounds that feature heavily in grey-market and biohacking communities. Only one compound is currently in clinical trials: kisspeptin in clinical formulations, being studied for its role in reproductive endocrinology. Oxytocin, while approved, sits at the intersection of hormonal and behavioural research, with an evidence base that extends well beyond its licensed obstetric indications.